2022年10月24日

NeoChord最近宣布从临床研究的积极成果经导管NeXuS僧帽弦齿修复系统。公司的全球早期可行性研究治疗的患者经导管连结系统,在为期一年的随访,结果显示显著的临床效益和患者生理改善,据该公司。NeoChord的研究结果显示pre-procedure二尖瓣返流(MR)严重等级(4 +)减少跟踪,通过所有后续的间隔保持不变。结果还显示显著改善左心室射血分数及左心室维度。“我们很高兴开始报道在1年随访期间患者的结果。这些令人印象深刻的结果构建在我们现有的身体健壮的临床证据和NeoChord不仅代表了一个重要的里程碑,也是治疗二尖瓣返流。最重要的是,研究结果验证使用NeXuS的疗效和安全性系统执行multiple-chord单锚过程和进一步建立在非NeoChord的领导地位,跳动的心脏二尖瓣弦齿修复,”总裁兼首席执行官大卫·钟在一个新闻发布会上说。二尖瓣返流是一种最常见的心脏瓣膜疾病影响数以百万计的世界各地的人们。如果条件不及时治疗,可能导致慢性心力衰竭。二尖瓣返流的特点是血液内泄漏向后心脏破裂造成的本机和弦和二尖瓣的无法正常关闭。 NeoChord’s NeXuS transcatheter mitral chordal repair device restores function in patients with primary mitral regurgitation. It maintains the natural physiologic functionality of the mitral valve and is deployed through the vein using a transfemoral delivery catheter that is navigated transeptally to the diseased native mitral valve. “These are compelling results for the future of minimally invasive transcatheter chordal repair, a procedure poised to drive positive outcomes and patient benefits by maintaining the physiologic construction of the mitral valve,” said Dr. Azeem Latin, section head and director of interventional cardiology and structural heart interventions at Montefiore Medical Center. “This procedure is a promising addition to the mitral toolbox and affords the heart team with an option to provide patients with an interventional approach to a surgically-proven technique.”